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development and progression of cancer
Ian F. GODSLAND
Endocrinology and Metabolic Medicine, Imperial College London, Praed Street, London W2 1PG, U.K.
ABSTRACT
Experimental, epidemiological and clinical evidence implicates insulin resistance and its
accompanying hyperinsulinaemia in the development of cancer, but the relative importance of
these disturbances in cancer remains unclear. There are, however, theoretical mechanisms by
which hyperinsulinaemia could amplify such growth-promoting effects as insulin may have, as well
as the growth-promoting effects of other, more potent, growth factors. Hyperinsulinaemia may
also induce other changes, particularly in the IGF (insulin-like growth factor) system, that could
promote cell proliferation and survival. Several factors can independently modify both cancer risk
and insulin resistance, including subclinical inﬂammation and obesity. The possibility that some
of the effects of hyperinsulinaemia might then augment pro-carcinogenic changes associated with
disturbances in these factors emphasizes how, rather than being a single causative factor, insulin
resistance may be most usefully viewed as one strand in a network of interacting disturbances that
promote the development and progression of cancer.
INTRODUCTION
Insulin resistance is a state of reduced sensitivity
of insulin-responsive tissues to insulin and its key
consequences include an impaired ability of insulin
to suppress hepatic glucose production and stimulate
peripheral glucose elimination. Circulating glucose levels
would, therefore, be expected to rise with insulin
resistance, but glucose is insulin’s principal secretagogue
and, providing β-cell function is adequate, insulin
secretion increases to overcome insulin resistance and
glucose levels are normalized. The resulting ‘com-
pensatory hyperinsulinaemia’ is a hallmark of insulin
resistance.
Insulin resistance coincides with an increased risk
of cancer in a variety of conditions, including aging,
physical inactivity [1], obesity [2], central body fat
distribution [3], Type 2 diabetes [4], hyperglycaemia [5],
the metabolic syndrome [6], liver disease [7], subclinical
inﬂammation [8], acromegaly [9], a high-glycaemic-
index diet [10] and a high-saturated-fat diet [11], and
there is extensively reviewed evidence linking measures
associated with insulin resistance with the subsequent
development ofcancer orpre-cancerouschanges [12–21].
These reviews have, however, tended to focus on speciﬁc
conditions, e.g. diabetes, obesity or colorectal cancer, or
on epidemiological rather than experimental evidence.
The present review begins by highlighting key aspects
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oftheexperimental,epidemiologicalandclinicalevidence
thatjustifyanin-depthconsiderationofinsulinresistance
and hyperinsulinaemia as factors in carcinogenesis. It
then examines the various mechanisms by which insulin
resistanceanditsaccompanyinghyperinsulinaemiacould
have an impact on cancer risk. The review also makes
a distinction between promotion of cancer by insulin
resistance and hyperinsulinaemia and promotion of
cancer by conditions that coincidentally cause insulin
resistance and hyperinsulinaemia.
EXPERIMENTAL, EPIDEMIOLOGICAL AND
CLINICAL EVIDENCE FOR LINKS BETWEEN
INSULIN RESISTANCE, HYPERINSULINAEMIA
AND CANCER
Experimental studies
Azoxymethane induction of colon cancer or pre-
cancerous aberrant crypt foci in the rat has provided
the most widely used experimental model with which
links between insulin resistance and cancer have been
evaluated. Tumorigenesis in this model is enhanced by
injection of medium-acting insulin [22,23], and calorie
restriction, perhaps the most familiar means of reducing
insulinresistance,diminishesthedevelopmentofaberrant
crypt foci [24]. Calorie restriction is also effective in
other animal models [25,26]. Low fat in the diet provides
additionalprotection[27]andthisemphasizesfurtherthe
possible importance of insulin resistance, given that low-
fat diets are associated with reduced insulin resistance
independent of calorie content [28]. Conversely, high
calorie intake correlates signiﬁcantly with pre-cancerous
changes [29], and this effect is again modulated by
dietary composition, the most tumorigenic being a high-
fat diet [30]. It is worth noting that, in an animal
model of breast cancer, the presence of obesity had no
apparent effect on mammary tumour development, but
thecarcinogenemployedwasmoreabletopromotecolon
cancer [31]. Insulin resistance and hyperinsulinaemia are
typical of obesity, so this observation draws attention to
the possibility that insulin resistance may be particularly
important in colon cancer.
Bruce and co-workers [32] have extended the dietary
studies to include an evaluation of accompanying
changes in insulin resistance and insulinaemia. The
development of colonic aberrant crypt foci was preceded
by insulin resistance and hyperinsulinaemia, and there
was a signiﬁcant positive relationship between the
size of aberrant crypt foci and non-fasting insulin
concentrations[29].Astrongerrelationshipwasobserved
with increasing OGTT (oral glucose tolerance test)
glucose concentrations which, when resulting from
dietary modiﬁcation, would be expected to reﬂect
increasing insulin resistance. In subsequent experiments,
Table 1 Correlation coefﬁcients for the relationships
between aberrant crypt foci and indices and measures
of insulin resistance and insulinaemia in Fischer 344 rats
initiated by azoxymethane and given diets differing in
calorie and saturated fat content (Koohestani et al. [29])
or saturated fat content (Tran et al. [33])
ACF, aberrant crypt foci; AUC, area under the curve.
Correlation with
Study ACF size/number Signiﬁcance
Koohestani et al. [29] (n=98)
Fasting plasma insulin 0.39 <0.01
OGTT glucose AUC 0.67 <0.001
Tran et al. [33] (n=24)
OGTT 180 min insulin 0.42 <0.05
Clamp insulin sensitivity −0.52 <0.01
a positive relationship was observed between the
number of aberrant crypt foci and insulin concentrations
3 h following an oral glucose load, but a stronger
relationship was apparent with a direct measure of
insulin sensitivity obtained using the euglycaemic–
hyperinsulinaemic clamp [33]. The signiﬁcant correlates
of precursors of colon cancer were, therefore, those
that might be expected to express most accurately net
insulin exposure. Key ﬁndings from these experiments
are summarized in Table 1.
Epidemiological studies
A complicating factor in evaluating whether experi-
mental associations between insulin resistance and cell
proliferation and survival translate into increased risk
in humans has been the difﬁculty in assessing insulin
resistance, requiring as it does quantiﬁcation of the
rate of elimination of glucose from the blood relative
to the accompanying plasma insulin concentration.
Plasma insulin concentrations can, nevertheless, provide
a surrogate index since, in the presence of adequate β-cell
function, the degree of compensatory hyperinsulinaemia
is directly related to the degree of insulin resistance.
C-peptide may provide a more effective index of
insulinaemia as it is secreted simultaneously and in
equimolar quantities with insulin but has a longer plasma
half-life, which may render it less subject to individual
variation. Associations between insulin or C-peptide
and cancer have been evaluated in a number of studies.
Studies of colorectal cancer are divided between those
showing no association [34–38] or a signiﬁcant positive
association [3,39–44], although three studies have found
signiﬁcantly higher insulin or C-peptide concentrations
among patients in whom colorectal adenoma has been
detected [45–47], particularly in those with advanced
lesions [45]. As with colorectal cancer, studies are
divided for breast cancer (no association [48–56]; positive
association [57–64]), endometrial cancer (no association
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[65,66]; positive association [67–69]) and prostate cancer
(no association [70–72]; positive association [73,74]).
Two studies of pancreatic cancer both found a positive
association [75,76].
Studies of colorectal, breast, endometrial and pancre-
atic cancer were the subject of a meta-analysis by Pisani
[19] published in 2008. The majority of studies were
population-based and, for colorectal and endometrial
cancers, there was little difference between prospective
and cross-sectional studies. Pisani did, however, note
that, for breast cancer, prospective studies all showed
no association with insulin or C-peptide, with all of the
evidence for a positive association coming from cross-
sectional studies. Positive associations could, therefore,
reﬂect secondary effects of existing cancer in the cases.
However, more recently, two prospective analyses from
the U.S. Women’s Health Initiative Observational Study
have reported a positive association between insulin con-
centrations and incident breast cancer [60,61]. Import-
antly, one of these evaluated serial insulin measurements
[61],whichwouldbeexpectedtoprovideamoreaccurate
assessment of net insulin exposure than a single baseline
measure. The serially derived insulin measures showed
an appreciably stronger relationship with incident breast
cancer than the single baseline measurements.
Epidemiological studies of the relationships between
insulin, C-peptide and cancer vary considerably in study
design and the extent to which confounding factors
have been taken into account. However, the majority
standardized for the principal confounder, adiposity.
The extent to which there is a continuous or threshold
relationship between insulinaemia and cancer is difﬁcult
to assess, the majority of studies simply comparing risk
in the top and bottom percentiles. There is, however,
some evidence for a continuous relationship [43]. The
weight of epidemiological evidence, therefore, suggests
that hyperinsulinaemia (and, by implication, insulin
resistance) is a risk factor for cancer and it should be
noted that, with studies divided between those showing
no association or a positive association, the weight
of evidence favours a positive association. Only with
prostate cancer has there been any evidence for a lower
risk of cancer with elevated insulin levels [77,78]. Studies
of prostate cancer will be confounded by the low
androgen concentrations, and therefore lower risk of
prostate cancer, that may be found in association with
insulin resistance. Nevertheless, as mentioned above,
there are also studies showing no association [70–72] or a
positive association [73,74] between prostate cancer and
insulinaemia. Relative risks for all studies of colorectal,
breast, endometrial and pancreatic cancer in the meta-
analysis of Pisani [19] are summarized in Table 2, with
estimates for prostate cancer from the meta-analysis of
Hsing et al. [18].
Other indices of insulin resistance or hyper-
insulinaemia include plasma leptin concentrations, the
Table 2 Summary relative risk estimates for plasma insulin
or C-peptide as predictors of colorectal, breast, endometrial
and pancreatic cancer from the meta-analysis of Pisani [19]
and for insulin as a predictor of prostate cancer from the
meta-analysis of Hsing et al. [18]
CI, conﬁdence interval.
Type of cancer Relative risk (95% CI) Number of cases
Colorectal 1.35 (1.13–1.61) 1257
Breast 1.26 (1.06–1.48) 1164
Endometrial 1.11 (0.74–1.65) 388
Pancreatic 1.70 (1.10–2.63) 209
Prostate 1.53 (1.01–2.32) 220
coincident insulin-resistance-related cardiovascular risk
factors of the metabolic syndrome and polymorphisms
of the insulin signalling system. As with measures of
insulinaemia, studies are divided according to whether
they show no signiﬁcant association or a signiﬁcant
positive association between these indices and cancer risk
[12–18,79–81]. It is noteworthy, however, that for the
metabolic syndrome, which would be expected to reﬂect
long-term insulin resistance and hyperinsulinaemia, the
weight of evidence appears to favour a signiﬁcant
positive association [6,17,18,38,82–87]. It should also be
noted that insulin-resistance-related abnormalities may
be associated, not only with cancer itself, but also
with more aggressive cancer or with mortality from
cancer in those with existing cancer [88–92]. Equivocal
evidence regarding diabetes mellitus may reﬂect a lack
of discrimination between hypo- and hyper-insulinaemic
formsofdiabetesmellitus[17,93]andpossibledifferences
according to diabetes therapy [21] (see the next section).
Clinical evidence
Restoration of insulin action by a reduction in insulin
resistance and replacement of plasma insulin is central
to the treatment of diabetes mellitus, and monitoring
of the long-term effects of the different treatments
available has provided suggestive evidence regarding
links between insulin resistance, hyperinsulinaemia and
cancer. A number of insulin-sensitization agents have
recently become available, but only metformin has
been in use long enough for reliable conclusions to be
drawn regarding its effects on cancer in vivo. Metformin
augments signalling via AMPK (AMP-activated protein
kinase), resulting in inhibition of hepatic glucose and
lipid synthesis and increased muscle glucose uptake
[94]. Consequently less insulin is needed to achieve
these effects and a net insulin sensitization is apparent.
Additionally, AMPK activation can inhibit cell growth
and proliferation, possibly via inhibition of the mTOR
(mammalian target of rapamycin) complex [95], and
there are now several studies showing a reduced risk
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of cancer in patients treated with metformin [96–99]. It
could be argued, however, that this reﬂects metformin’s
intracellular actions rather than any effect it may have
on insulin resistance and hyperinsulinaemia. Moreover,
evidence from in vitro studies indicates that metformin
also has effects on cell proliferation via intracellular
targets other than AMPK [100,101].
Injectionofinsulinbypatientswithdiabetestocontrol
their blood glucose levels has been a mainstay of Type 1
diabetestherapyforover80 yearsandisalsoanimportant
option in the treatment of Type 2 diabetes. There is some
evidence that insulin therapy can augment colorectal
cancer risk in patients with Type 2 diabetes [102,103].
Importantly,oneofthesestudiescorrectedformetformin
use, this being likely to be more frequent in the non-
insulin-using controls and to be associated with lower
colorectal cancer risk [102]. Moreover, that study found
that risk increased signiﬁcantly with increasing duration
of chronic insulin use. Further suggestive evidence comes
from a study published recently based on a German
insurance fund cohort in which a signiﬁcant increase in
the risk of malignant neoplasm or cancer mortality was
observedwitheachS.D.increaseindoseofhumaninsulin
[104].
Recombinant DNA technology has enabled the
construction of insulin analogues with enhanced
absorption properties and a more sustained biological
effect on account of a higher afﬁnity of binding to
the insulin receptor. Such properties might also be
expected to enhance any effects insulin might have on
cellproliferationandsurvival.Adose-dependentincrease
in malignant tumour formation was observed in rats
injected with one of the earliest of these analogues to
be investigated, B10-Asp (AspB10 insulin), which has
an aspartate residue substituted at the B10 position of
the insulin molecule [105]. A 7-fold increase in the
rate of proliferation of cultured human cancer cells was
observed with this analogue [106], and similar effects
have been reported in vitro with other analogues [107].
Insulin analogues can undergo modiﬁcation at the site
of injection, so the relevance of proliferative effects
identiﬁed in vitro to in vivo risks is questionable. There
are, nevertheless, several observational epidemiological
studies that link use of some insulin analogues with
increased risk of cancer [98,104,108,109]. Although
controversial [110,111], the possibility has been raised
that the pro-proliferative effects of insulin analogues
result primarily from enhanced activation of the IGF-1
(insulin-like growth factor-1) receptor [21]. Their
relevance to any effects native human insulin may have
are, therefore, questionable.
It should be noted that the other major therapy option
for increasing circulating native insulin levels is use of
insulin secretagogues, of which the sulfonylurea drugs
have been available the longest. There is some evidence
suggesting an increased risk of cancer in patients using
theseagents[97–99,112],butﬁrmconclusionsaredifﬁcult
because of the inclusion of reduced risk metformin users
in the comparison groups. Sulfonylurea users may be
at a somewhat lower risk than insulin users [97], but
information in this area is very limited and, even if an
increased risk was conﬁrmed, a pharmacological effect of
these drugs cannot be excluded.
MITOGENIC AND ANTI-APOPTOTIC EFFECTS
OF INSULIN
Growth promotion via classical insulin
signalling
The possibility that insulin might increase cell prolif-
eration in vivo was highlighted decades ago by Stout
and Vallance-Owen [113] in relation to the development
of atherosclerosis and, at the same time, in vitro and
in vivo studies were indicating that many tumours might
have an absolute dependence on insulin for continuing
growth [114,115]. Since then, there has been considerable
progress in elucidating how insulin could promote cell
proliferation and survival. Insulin action begins with
bindingtoitsspeciﬁcreceptor,atransmembranereceptor
tyrosine kinase. Signalling by the activated receptor
involves autophosphorylation of tyrosine residues in
the intracellular domain, which then promotes the
phosphorylation of IRS-1 (insulin receptor substrate-1)
and transmission of the insulin signal via two major
phosphorylation cascades. These are distinguished by
their principal mediators: PI3K (phosphoinositide 3-
kinase) and MAPK (mitogen-activated protein kinase),
as illustrated in Figure 1.
Signalling via the PI3K pathway involves the
interaction of phosphorylated IRS-1 with the p85
regulatory subunit of PI3K and, as a consequence,
activation of the PI3K p110 catalytic subunit. Activated
PI3K locates to the cell membrane where it catalyses the
production of PtdIns(3,4,5)P3. PtdIns(3,4,5)P3 stimulates
the translation of the serine/threonine protein kinase
Akt to the cell membrane, where it is phosphorylated
by the PtdIns(3,4,5)P3-dependent protein kinase PDK1
(phosphoinositide-dependent kinase 1). Akt is capable
of stimulating the phosphorylation and consequent
inhibition or activation of a broad range of proteins that
affectcellgrowth,divisionandsurvivalaswellaslipidand
carbohydrate metabolism, for example the pro-apoptotic
Bcl-2 family member BAD, the metabolism and growth-
related Fox (forkhead box) transcription factors such as
Foxa2 and FOXO1a, and the growth-related mTOR and
its downstream effector kinase p70S6K (p70 S6 kinase).
Signalling via the PI3K pathway is also a key factor
in the translocation of GLUT-4 glucose transporters
to the cell membrane. The importance of signalling via
the PI3K pathway for cell proliferation and survival is
evidenct from the high prevalence in a variety of cancers
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Figure 1 Principal signalling pathways activated by the insulin receptor
Positive inﬂuences are shown by lines ending in arrows and inhibitory inﬂuences by lines ending in bars. MEK, MAPK/extracellular-signal-regulated kinase kinase; PIP3,
PtdIns(3,4,5)P3; PKC, protein kinase C; triglyceride, triacylgycerol.
of a loss-of-function of the PtdIns(3,4,5)P3-phosphatase
PTEN (phosphatase and tensin homologue deleted on
chromosome 10), which results in elevated levels of
PtdIns(3,4,5)P3 and enhanced PI3K signalling [116].
Phosphorylated IRS-1 can also mediate the formation
of a complex between the adaptor protein Grb2 (growth-
factor-receptor-bound protein 2) and the guanine
nucleotide-exchange factor mSos (mammalian Son of
sevenless). The Grb2–mSos complex can then promote
GTP loading and consequent activation of the small-
molecular-mass GTPase p21Ras, which lies at the head
of the MAPK signalling cascade and which provides
a point of convergence for signalling by a number of
growth factors. Via a series of intermediate kinases,
activated p21Ras promotes the activation of MAPKs,
which then activate transcription factors involved in
cell proliferation. The importance of signalling via the
Ras/MAPK pathway for cell proliferation and survival is
shown by the high prevalence of p21Ras overexpression
in a range of different cancers [117].
In vitro studies, including studies of cancer cells
[118], provide ample evidence for the promotion of
cell division by insulin. However, supra-physiological
insulin concentrations have generally been used in these
studies and it has been questioned whether, on its own,
insulin binding to the insulin receptor has any growth-
promoting effects [119]. Nevertheless, the in vivo milieu
in which insulin operates may be very different from in
vitro conditions and, as will be shown, insulin can induce
other changes that could amplify any growth-promoting
properties it may have. It could be objected that the
compensatory hyperinsulinaemia of insulin resistance
merely restores insulin signalling to non-resistant levels
so, in principle, no additional drive to cell division and
survival might be expected. This is likely to be true of
signalling via the PI3K pathway, which also mediates the
glucoregulatory effects of insulin. There is, nevertheless,
someevidencefromaninvitrostudyinbreastcancercells
thatinsulinsignallingviatheMAPKpathwayispreserved
despite inhibition of IRS-1/PI3K signalling [120]. The
possibility that compensatory hyperinsulinaemia might
provide additional drive to cell proliferation via the
MAPK pathway is illustrated in Figure 2.
Other growth-promoting effects of insulin
Small-molecular-mass GTPases play a key role in the
signalling pathways involved in cell proliferation and
there is evidence, largely from the work of Goalstone,
Drazninandco-workers[121–123],forspeciﬁcactivation
of these proteins and ampliﬁcation of their effects by
insulin. p21Ras is among the most prominent of these
enzymes and prenylation of p21Ras with a farnesyl
moiety by the enzyme farnesyl transferase is an essential
step in anchoring p21Ras to the plasma membrane in
readiness for GTP loading and signalling via the MAPK
pathway. Insulin can activate farnesyl transferase by
phosphorylation of its regulatory α subunit [121], and
insulin-induced increases in p21Ras farnesylation have
indeed been shown to be associated with increased GTP
loading of membrane-bound p21Ras [122]. Activation of
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Figure 2 Hypothetical scheme for enhanced cell growth and survival in insulin resistance
In uncompensated insulin resistance (upper panel), signalling via the PI3K pathway is diminished, glucose uptake by the cell via GLUT-4 transporters is reduced,
suppression of gluconeogenesis is reduced and glucose levels rise. In compensated insulin resistance (lower panel), the pancreas responds to the rise in glucose levels
with increased insulin secretion, insulin levels rise, signalling through the PI3K pathway is restored and cell glucose uptake and gluconeogenesis are normalized.
However, the increased insulin concentrations increase signalling via the kinases of the MAPK pathway {p21Ras, Raf, MEK [MAPK/ERK (extracellular-signal-regulated
kinase) kinase] and ERK} to increase cell proliferation and survival.
farnesyl transferaseappears to be mediated via the insulin
receptor, as shown by increased levels of farnesylated
p21Ras in cells overexpressing insulin receptors and
reducedlevelsincellsexpressingamutantinsulinreceptor
with impaired function [123]. These studies also suggest
that farnesyl transferase activation by insulin is not
mediated by the IRS-1/PI3K pathway, but via another
target of the activated insulin receptor, Shc, which then
promotes Grb2/mSos recruitment, p21Ras activation
and phosphorylation of farnesyl transferase via MAPK
pathway activation. Different isoforms of Shc that can
be phosphorylated by the activated insulin receptor
[124] include the p52 isoform which, upon tyrosine
phosphorylation, activates p21Ras and the p66 isoform
which has an additional domain with a phosphorylatable
serine residue and acts as a competitive inhibitor of
p21Ras activation by the other isoforms [125].
This stimulation of farnesyl transferase activity
appears to be speciﬁc to insulin [126], and prolonged
hyperinsulinaemiahasbeenshowntoincreasethecellular
pool of farnesylated p21Ras and loading of p21Ras with
GTP[127,128].Thiseffectisinadditiontothegeneralup-
regulation of p21Ras-GTP associated with growth factor
signallinganditcan,therefore,synergizewithstimulation
of the guanine nucleotide-exchange activity of mSos by
insulin or other growth factors to amplify growth factor
signalling [129,130]. These interactions are illustrated in
Figure 3.
Up-regulation of insulin receptors and
insulin-regulated intracellular signalling
molecules
Carcinogenesis is a multifactorial multistage process
and one of these stages can include overexpression of
insulin receptors. The compensatory hyperinsulinaemia
of insulin resistance could, therefore, provide an
additional stimulus to cell proliferation and survival
in situations where insulin signalling has already been
rendered hypersensitive by increased expression of
insulin receptors. In non-malignantly transformed cells
overexpressing insulin receptors, exposure to insulin can
result in a malignantly transformed phenotype [131,132].
Insulinreceptorsmaybeoverexpressed2–6-foldincancer
cells [133–135]; moreover, although the up-regulated
receptors can appear structurally normal, the sensitivity
of their receptor tyrosine kinase activity is increased
[136]. Two isoforms of the insulin receptor exist, the A
isoform predominating in fetal tissues and the B isoform
in adult tissues. In addition to binding insulin, the A
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Figure 3 Farnesylation of p21Ras causes it to locate to the plasma membrane where it can undergo GTP loading, which is
essential for signalling via the MAPK pathway
Insulin increases activation of farnesyl transferase, which increases farnesylation of p21Ras. As a consequence, the pool of p21Ras-GTP is increased. This has the effect
of amplifying growth factor signalling via the MAPK pathway. MEK, MAPK/ERK kinase.
form of the receptor binds IGF-2 and, in cancer cells
overexpressing insulin receptors, the A form appears to
predominate [137]. Overexpression of insulin receptors
thereforeexposesthecelltothegrowth-promotingeffects
of IGF-2.
Cancer cells appear to loose their ability to down-
regulate insulin receptors in response to hyperinsulin-
aemia [138] and in cells with up-regulated insulin
receptors, a given concentration of insulin can increase
production of p21Ras-GTP 7-fold compared with
normal cells [139]. The observation that p21Ras-GTP,
farnesylated p21 Ras and phosphorylated Shc are all
increased in cells overexpressing insulin receptors or
overexpressing a mitogenically active mutant insulin
receptor emphasizes the functional consequences of
receptor overexpression [135,140]. As well as interacting
with up-regulated insulin receptors, the compensatory
hyperinsulinaemiaofinsulinresistancecouldalsointeract
withtheup-regulationofintracellularmediatorsinvolved
in growth factor signalling frequently observed in
carcinogenesis. An example is provided by p21Ras itself,
which,whenoverexpressed,cangreatlyenhancetheeffect
of insulin on cell growth [141].
INSULIN RESISTANCE, HYPERINSULINAEMIA
AND SIGNALLING VIA THE IGF-1 RECEPTOR
IGF-1, insulin resistance and cell
proliferation and survival
IGF-1 signalling via the IGF-1 receptor has effects
on cell proliferation and survival that are appreciably
stronger than those of insulin [142]. IGF-1 can act as
a potent growth factor for cancer cells both in vivo
[143] and in vitro [144], and in vivo overexpression of
IGF-1 can promote tumour formation [145], whereas its
down-regulation can inhibit tumorigenesis [146]. IGF-1
can overcome the beneﬁcial effect of calorie restriction
in animal models of cancer [147] and can increase
expression of angiogenic factors in cancer cells [148].
Epidemiological evidence supports a role for elevated
circulatingIGF-1levelsinthedevelopmentofavarietyof
cancers, including colorectal, prostate and breast cancers
[149] (although an inverse relationship has been reported
for free IGF-1 levels [67]). It should also be noted
that stimulation of PI3K or MAPK signalling via the
IGF-1 receptor can promote phosphorylation of TAF-1
(transcriptional activation function-1) of the oestrogen
receptor, thus promoting oestrogen-independent cell
growth and division in oestrogen-sensitive tissues [150].
There is considerable homology between the insulin
receptor and the IGF-1 receptor, and insulin can bind to
and activate the IGF-1 receptor. Insulin could, therefore,
enhanceIGFsignallingbydirectstimulationoftheIGF-1
receptor [151], although the relevance of this is uncertain
[152]. Nevertheless, given that signalling via the IGF-1
receptor is more tightly linked to growth promotion,
anyaugmentationofIGF-1-receptor-mediatedsignalling
could markedly affect cell proliferation and survival. In
accordance with this, relatively minor increases in serum
IGF-1 concentrations are associated with an increased
risk of prostate [153,154], breast [155], colon [156] and
lung [157] cancers.
Indirect effects of insulin on IGF signalling
Insulin can up-regulate human hepatic GH (growth
hormone) receptors [158], and receptor-mediated GH
signalling in the liver is the principal stimulus for IGF-1
release [159]. Hyperinsulinaemia could, therefore, spe-
ciﬁcally augment IGF-1 levels. The potential importance
of such an effect is suggested by the observations that, in
contrastwithIGF-1,IGF-2levelsappeartobeunaffected
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Figure 4 Interaction between insulin resistance and cell proliferation and survival
Theoretically, interactions between the effects of insulin resistance and hyperinsulinaemia could lead to ampliﬁcation of the cell proliferation and survival signals induced
by insulin. This ampliﬁcation will be even greater against a background of insulin or IGF-1 receptor overexpression or growth signalling protein overexpression. The
ability of insulin to increase the pool of p21Ras-GTP by enhancing p21Ras farnesylation has the potential to amplify further these effects.
by GH levels [160] and do not predict incident cancer
[156]. As IGF-1 signalling involves similar pathways
to those utilized by insulin, another mechanism by
which insulin could amplify IGF-1 signalling could
involveinsulin’sabilitytostimulatep21Rasfarnesylation.
Moreover,aswiththeinsulinreceptor,theIGF-1receptor
is frequently overexpressed in cancer cells [161,162]. In
addition to amplifying any signalling by insulin via the
IGF-1 receptor, overexpression of the IGF-1 receptor
in cancer cells will augment the formation of insulin
receptor/IGF-1 receptor hybrids. This could increase the
possibility of cross-talk, whereby insulin binding
totheinsulinreceptormoietyoftheheterodimeractivates
theIGF-1receptormoiety[163],andthereisevidencefor
this in relation with hybrids with the A isoform of the
insulin receptor [164].
IGFBPs (IGF-binding proteins)
Insulin could affect IGF-1 signalling further by
modulating the availability of IGFBPs. Six IGFBPs have
been identiﬁed and the most abundant, IGFBP-3, binds
approx. 80% of circulating IGF-1 and has intrinsic
anti-tumorigenic properties [165], possibly mediated
by inhibition of farnesyl transferase activity [166].
There is also evidence that IGFBP-3 may promote
apoptosis [167,168]; however, hepatic production of
IGFBP-3andformationoftheIGF-1–IGFBP-3complex
appears to be positively controlled by GH, which,
given the up-regulation of GH receptors by insulin
described above, would predict higher IGFBP-3 levels
in association with compensatory hyperinsulinaemia
[169]. These interactions would then suggest an anti-
tumorigenic action of insulin.
In contrast, hyperinsulinaemia suppresses IGFBP-1
levels [170,171] and, although IGFBP-2 is not
acutely regulated by insulin, there is some evidence
that chronically low levels of insulin are associated
with an increase in IGFBP-2 [172]. How important
these effects are with regard to the control of IGF
availability might be questioned given that less than
25% of IGF appears to be bound by these proteins
[173]. However, although IGFBP-3 is responsible for
the bulk of IGF binding, it is the smaller, capillary
permeable, rapidly turning over pool of IGFBPs, which
includes IGFBP-1 and IGFBP-2, that may be important
in modulating IGF bioactivity [173,174]. Suppression of
the levels of these proteins by insulin might, therefore,
increase the extravascular availability of bioactive IGF-1,
although much more evidence is needed to clarify the
complex dynamic relationships that are likely to be
involved.
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Figure 5 Coincident promotion of insulin resistance and cell proliferation and survival in inﬂammation
Activated cells of the immune system release cytokines and ROS, which induce insulin resistance via JNK and cell proliferation and survival via NF-κB. Positive
inﬂuences are shown by lines ending in arrows and inhibitory inﬂuences by lines ending in bars.
INSULIN-RESISTANCE-RELATED
PRO-CARCINOGENIC CHARACTERISTICS
Insulin resistance and its compensatory hyperinsulin-
aemia have effects that can promote cancer and
these effects can interact and synergize with other
growth-promoting changes, as illustrated in Figure 4.
Nevertheless, insulin resistance and hyperinsulinaemia
may be a consequence of other processes that can
themselves promote cancer by other pathways. Two
key areas in this respect are increased activation of
the inﬂammatory system and increased adiposity, both
of which can induce insulin resistance and both of
which may promote the development and progression
of cancer independently of their effects on insulin
resistance.
Activation of inﬂammatory mediators
Inﬂammation, chronic and subclinical, has come to be
recognized as a key factor in tumorigenesis and cancer
progression [175–177]. One means by which activated
cells of the immune system exert their protection against
pathogens is by production of ROS (reactive oxygen
species), and ROS can disrupt insulin signalling by
activating JNK (c-Jun N-terminal kinase). JNK, in turn,
increases the serine phosphorylation of IRS-1, decreases
thetyrosinephosphorylationofIRS-1andinhibitsserine
phosphorylation of Akt, each of which contribute to
reduced insulin signalling [178]. ROS can also cause
oxidative damage to DNA, a key factor in the somatic
mutations that underlie tumorigenesis [179]. It should
be noted that, as well as inducing insulin resistance,
production of ROS can also be increased by some of the
consequences of insulin resistance, including elevations
in glucose levels [180] and increased β-oxidation of fatty
acids [181].
Activation of inﬂammatory pathways can induce
insulin resistance by a variety of other mechanisms [182].
For example, signalling by TNF-α (tumour necrosis
factor-α)viatheTNFreceptorcanactivateJNK.Another
possibility involves signalling via NF-κB (nuclear factor
κB), which is promoted by an inhibitor of NF-κB
inactivation, IKKβ [IκB (inhibitor of NF-κB) kinase β].
The importance of NF-κB in the induction of insulin
resistance is apparent in the improvements in insulin
sensitivity resulting from inhibition of IKKβ by high
dose salicylate [183]. Equally, the importance of NF-
κB in the promotion of carcinogenesis is apparent in
the reduction in risk of cancer associated with the
use of aspirin and other NSAIDs (non-steroidal anti-
inﬂammatory agents) [184], which is mediated by the
inhibition of signalling via NF-κB [185]. A further
convergence between inﬂammation, insulin resistance
and cancer is observed in relation to the nuclear receptor
PPAR-γ (peroxisome-proliferator-activated receptor-γ).
Asawell-establishedmediatorofinsulinaction,PPAR-γ
can also antagonize NF-κB [186] and can inhibit pro-
carcinogenic changes in human colon cancer cells [187].
Interactions between inﬂammation, insulin resistance
and cell proliferation and survival are illustrated in
Figure 5.
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Figure 6 Coincident promotion of insulin resistance and cell proliferation and survival in obesity
Positive inﬂuences are shown by lines ending in arrows and inhibitory inﬂuences by lines ending in bars.
Obesity
Increased adiposity is a major determinant of insulin
resistance, as well as being a risk factor for cancer.
It is associated with increased NEFAs (non-esteriﬁed
fatty acid levels) which, by competing with glucose as
a metabolic fuel, can induce insulin resistance and can
alsoincreasefattyacidoxidationandproductionofROS.
Moreover, adipose tissue, with its resident macrophages,
can release a variety of so-called ‘adipokines’ that include
both proteins with signalling properties and cytokines.
The cytokines include TNF-α and IL-6 (interleukin-6),
both of which have pro-oncogenic effects and can induce
insulin resistance [188]. Visceral adipose tissue appears
to be a particularly rich source of adipokine cytokines
[189], and insulin resistance has a stronger relationship
with visceral fat than with overall adiposity. Visceral fat
mayparticularlypredisposetothedevelopmentofcancer
[3,190], especially in post-menopausal women [191–193].
Among the adipokine proteins with signalling proper-
ties, leptin acts as an ‘adipostat’ by suppressing centrally
generated appetite signalling. Obesity is, however,
associated with leptin resistance and hyperleptinaemia.
Leptinconcentrationsarestronglycorrelatedwithinsulin
resistance[194],butleptinappearstohavepro-oncogenic
effects of its own since, in vitro, it can enhance
proliferation of both normal [195] and cancer [196] cell
lines and can stimulate angiogenesis [197]. Moreover, at
levelsobservedinobesity,leptinmaybeabletoinducethe
adipose tissue aromatase enzyme complex [198], which
would be expected to increase concentrations of the
mitogenic sex hormone oestradiol (see below).
Obesity is also associated with reduced levels of the
anti-inﬂammatory pro-apoptotic adipokine adiponectin.
Adiponectinisinverselyassociatedwithinsulinresistance
and this may reﬂect more than mere co-variation with
adiposity, since adiponectin has a number of effects at
the cellular level that could increase the sensitivity of
glucose and lipid metabolism to insulin via its activation
of the cell energy sensor AMPK and the nuclear receptor
PPAR-α [199]. As mentioned previously with regard to
metformin, activation of AMPK has anti-proliferative
effects, and there is evidence for this in relation to the
activation of AMPK signalling by adiponectin [200]. It
should be noted that adiponectin can inhibit TNF-α-
inducedphosphorylationofIKKβ and,consequently,the
activation of NF-κB [201].
Beyond the pro-inﬂammatory effects of increased
adiposity, adipose tissue can mediate potentially pro-
oncogenictransformationsingonadaloradrenalsteroids:
speciﬁcally, increased synthesis of oestradiol from
testosterone and oestrone from  4-androstenedione by
the aromatase enzyme complex. This increases oestradiol
concentrations, and oestradiol is a potent mitogen for
breast and endometrial tissue. The potential importance
of these interconversions is apparent in post-menopausal
women, in whom oestradiol levels are signiﬁcantly
correlated with BMI (body mass index), and the risk of
breastcancerassociatedwithBMIissubstantiallyreduced
by including endogenous oestrogen concentrations as
a covariate [202]. Interactions between obesity, insulin
resistanceandcellproliferationandsurvivalareillustrated
in Figure 6.
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Other factors related to insulin resistance
and cancer
Speciﬁcally with regard to the sex-hormone-dependent
cancers, i.e. cancers of the breast, prostate and endo-
metrium, SHBG (sex hormone-binding globulin) levels
are reduced in states of insulin resistance, apparently
due to a direct suppressive effect of hyperinsulinaemia
on SHBG production by the liver [203]. This could act
to increase the availability of free sex hormones [204]
and, therefore, favour the development of sex-hormone-
dependent cancers. Ampliﬁcation of oestradiol levels in
obesity could also result from induction of aromatase
activity by the pro-inﬂammatory adipokines TNF-α and
IL-6 [205], which, as mentioned above, will be present in
adipose tissue in relatively high concentrations.
Increased inﬂammation and obesity and decreased
SHBG provide extracellular points of focus that relate
to insulin resistance and have pro-carcinogenic effects
of their own. Conversely, there are several intracellular
pointsoffocusthatcanbothmediateinsulinsensitization
and diminish cell proliferation and survival. PPAR-γ
has already been mentioned in relation to inﬂammation.
Another, more recently recognized point of focus
is provided by the deacetylase SIRT1 (sirtuin 1).
Sirtuins are key mediators in the longevity associated
with calorie restriction [206], and sirtuin action can
modulatetheactivitiesofseveralkeytranscriptionfactors
(reviewedin[207,208]).Forexample,SIRT1candiminish
inﬂammatory pathway signalling by deacetylating the
p65 transcription factor subunit of NF-κB and can
deacetylate Foxo1, thus promoting transcription of the
adiponectin gene. It can also promote deacetylation
of Foxo3a, leading to enhanced expression of catalase,
the enzyme responsible for metabolizing H2O2 and
thus reducing ROS levels. SIRT1 can also enhance
post-receptor insulin signalling by increasing serine
phosphorylation of Akt and tyrosine phosphorylation
of the insulin receptor and IRS-1, primarily through
transcriptional repression of the phosphorylase Ptpn1
(protein tyrosine phosphatase, non-receptor type 1). The
actions of SIRT1 appear to depend on the nutritional
context in which they are studied, but their net effects
generally point to enhancement of insulin sensitivity.
Their effect on cancer risk is complicated by the fact
that, under normal conditions, there is a mutually
reinforced inverse relationship between SIRT1 and p53
[209,210]. Given the critical role of p53 in eliminating
DNA damage via apoptosis, its down-regulation would,
conventionally, be regarded as oncogenic. However,
SIRT1 can also inhibit cell cycle progression [211], so
it may be that it acts to provide a check on both
cell cycle progression and apoptosis, thus allowing
for more effective DNA repair [207]. In accord
with this, in vivo studies show a tumour-suppressive
effect of experimentally enhanced SIRT1 levels
[212].
DISCUSSION
There are plausible mechanisms by which insulin
resistance and hyperinsulinaemia could promote cancer
development and progression, but it remains to be
established how important these are. A number of
conditions that lead to insulin resistance, particularly
subclinical inﬂammation and obesity, have effects of
their own that are pro-carcinogenic. Therefore, in
epidemiological studies, detailed baseline and long-term
evaluation will be needed not only of insulin resistance
and hyperinsulinaemia, but also subclinical inﬂammation
and adiposity. To date, very few studies meet these
requirements.
The inter-relatedness of the various factors that
connect with insulin resistance and cancer risk is
illustrated in Figure 7, and it should be apparent
from this Figure that it may be unrealistic to consider
insulin resistance as a standalone cancer risk factor. Both
inﬂammation and obesity have effects of their own
that could promote cancer, but the hyperinsulinaemia
they induce may itself feedback and augment further
their effects on cell proliferation and survival. One
possibility for gaining a better understanding of the
relative importance of the role of insulin resistance
in cancer development may be to evaluate the co-
associated metabolic disturbances that insulin resistance
is characterized by, rather than insulin resistance itself.
Conventionally, insulin resistanceis quantiﬁed according
to its glucoregulatory effects, but it also has effects
on lipid metabolism and renal function. A measure
of the insulin resistance syndrome could, therefore,
provide a potentially useful index of whole-body insulin
resistance. Given the close relationship between insulin
resistance and hyperinsulinaemia, such a measure could
also provide a better index of net insulin exposure than
a single fasting insulin measurement or even insulin
concentrations in response to glucose challenge. It is
worth noting, as described above, that the evidence
for the metabolic syndrome (an approximate index of
insulin-resistance-relatedmetabolic disturbance)as arisk
factor for cancer is more consistent than for insulin
alone.
An important question that has yet to be resolved
is, to what extent is insulin resistance a risk factor for
cancer in general or for speciﬁc types of cancer? As
mentioned, there is some evidence for insulin resistance
being particularly related to colorectal cancer, and
studies speciﬁcally concerned with colorectal cancer
predominate. However, the majority of mechanisms
summarized in the present review could affect the risk
of any kind of cancer, with some additional mechanisms
applying to sex-hormone-dependent cancers. Colorectal
cancer is, nevertheless, a major cancer and insulin-
resistance-related factors could provide useful points of
intervention by analogy with cigarette smoking and lung
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Figure 7 Selected key inter-relationships in an insulin-resistant pro-carcinogenic state associated with increased
inﬂammation, obesity and reduced levels of SIRT1
Potentially beneﬁcial effects, with regard to reducing both insulin resistance and cell proliferation and survival, that are diminished in this state are shown by the broken
lines. Positive inﬂuences are shown by lines ending in arrows and inhibitory inﬂuences by lines ending in bars. Variables independently reduced in insulin-resistant
states are shown by the solid arrows.
cancer, and sex hormone action and breast and prostate
cancer.
Recent reports of an increased incidence of cancer in
users of insulin analogues [98,104,108,109] highlight the
potential importance of insulin as a cancer risk factor.
However, from the clinical point of view, these are still
preliminaryobservations,withrelativelyshortfollow-up
times and inconsistencies in the types of cancer for which
an increased risk was apparent. Future studies will need
to focus on whether these are chance ﬁndings, whether
they reﬂect the inﬂuence of a particular at-risk subgroup
and, supposingthere is increased risk,whether this places
incidence rates among those using long-acting insulins
above those in the population in general. This latter point
reﬂects the possibility mentioned previously that some
patientswithdiabetesmayberelativelyhypoinsulinaemic
and, therefore, at relatively low risk of cancer. If such
patients form the comparison group in studies of long-
acting insulins, an exaggerated impression of risk may be
given.
In conclusion, it bears repeating that cancer is a
multifactorial process. Insulin itself does not induce
somatic cell mutations and cannot, therefore, be
considered a carcinogen. However, pre-malignant lesions
may be present in a high proportion of healthy
individuals, and whether these progress to an invasive
metastatic fatal cancer can depend on an extraordinarily
complex interacting network of errors, imbalances
and disturbances. It should be apparent from the
present review that insulin resistance and its associated
hyperinsulinaemiacouldformasigniﬁcantstrandinsuch
an e t w o r k .
FUNDING
The author’s work is funded by the Heart Disease and
Diabetes Research Trust.
REFERENCES
1 Giovannucci, E., Colditz, G. A., Stampfer, M. J. and
Willett, W. C. (1996) Physical activity, obesity, and risk of
colorectal adenoma in women (United States). Cancer
Causes Control 7, 253–263
2 Calle, E. E. and Thun, M. J. (2004) Obesity and cancer.
Oncogene 23, 6365–6378
3 Schoen, R. E., Tangen, C. M., Kuller, L. H., Burke, G. L.,
C u s h m a n ,M . ,T r a c y ,R .P . ,D o b s ,A .a n dS a v a g e ,P .J .
(1999) Increased blood glucose and insulin, body size, and
incident colorectal cancer. J. Natl. Cancer Inst. 91,
1147–1154
4 Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J. and
Thun, M. J. (2004) Diabetes mellitus as a predictor of
cancer mortality in a large cohort of US adults. Am. J.
Epidemiol. 159, 1160–1167
5 Rapp, K., Schroeder, J., Klenk, J., Ulmer, H., Concin, H.,
Diem, G., Oberaigner, W. and Weiland, S. K. (2006)
Fasting blood glucose and cancer risk in a cohort of more
than 140,000 adults in Austria. Diabetologia 49, 945–952
6 Trevisan, M., Liu, J., Muti, P., Misciagna, G., Menotti, A.
and Fucci, F. (2001) Markers of insulin resistance and
colorectal cancer mortality. Cancer Epidemiol.
Biomarkers. Prev. 10, 937–941
7 Bugianesi, E. (2007) Non-alcoholic steatohepatitis and
cancer. Clin. Liver Dis. 11, 191–207
8 Coussens, L. M. and Werb, Z. (2002) Inﬂammation and
cancer. Nature 420, 860–867
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Insulin resistance and cancer 327
9 Jenkins, P. J. (2004) Acromegaly and cancer. Horm. Res.
62, (Suppl. 1), 108–115
10 Augustin, L. S., Galeone, C., Dal Maso, L., Pelucchi, C.,
Ramazzotti, V., Jenkins, D. J., Montella, M., Talamini, R.,
Negri, E., Franceschi, S. and La Vecchia, C. (2004)
Glycemic index, glycemic load and risk of prostate cancer.
Int. J. Cancer 112, 446–450
11 Bruce, W. R., Wolever, T. M. and Giacca, A. (2000)
Mechanisms linking diet and colorectal cancer: the
possible role of insulin resistance. Nutr. Cancer 37,
19–26
12 McKeown-Eyssen, G. (1994) Epidemiology of colorectal
cancer revisited: are serum triglycerides and/or plasma
glucose associated with risk? Cancer Epidemiol.
Biomarkers Prev. 3, 687–695
13 Komninou, D., Ayonote, A., Richie, Jr, J. P. and Rigas, B.
(2003) Insulin resistance and its contribution to colon
carcinogenesis. Exp. Biol. Med. 228, 396–405
14 Giovannucci, E. (2003) Nutrition, insulin, insulin-like
growth factors and cancer. Horm. Metab. Res. 35,
694–704
15 Kaaks, R. (2004) Nutrition, insulin, IGF-1 metabolism
and cancer risk: a summary of epidemiological evidence.
Novartis Found. Symp. 262, 247–260
16 Cowey, S. and Hardy, R. W. (2006) The metabolic
syndrome: A high-risk state for cancer? Am. J. Pathol.
169, 1505–1522
17 Xue, F. and Michels, K. B. (2007) Diabetes, metabolic
syndrome, and breast cancer: a review of the current
evidence. Am. J. Clin. Nutr. 86, (Suppl), 823S–835S
18 Hsing, A. W., Sakoda, L. C. and Chua, S. C. J. (2007)
Obesity, metabolic syndrome and prostate cancer. Am. J.
Clin. Nutr. 86, (Suppl), 843S–857S
19 Pisani, P. (2008) Hyper-insulinaemia and cancer,
meta-analyses of epidemiological studies. Arch. Physiol.
Biochem. 114, 63–70
20 Renehan, A. G., Roberts, D. L. and Dive, C. (2008)
Obesity and cancer: pathophysiological and biological
mechanisms. Arch. Physiol. Biochem. 114, 71–83
21 Smith, U. and Gale, E. A. (2009) Does diabetes therapy
inﬂuence the risk of cancer? Diabetologia 52, 1699–1708
22 Tran, T. T., Medline, A. and Bruce, W. R. (1996) Insulin
promotion of colon tumors in rats. Cancer Epidemiol.
Biomarkers Prev. 5, 1013–1015
23 Corpet, D. E., Jacquinet, C., Peiffer, G. and Tach´ e, S.
(1997) Insulin injections promote the growth of aberrant
crypt foci in the colon of rats. Nutr. Cancer 27, 316–320
24 Steinbach, G., Kumar, S. P., Reddy, B. S., Lipkin, M. and
Holt, P. R. (1993) Effects of caloric restriction and dietary
fat on epithelial cell proliferation in rat colon. Cancer Res.
53, 2745–2749
25 Hursting, S. D., Perkins, S. N., Phang, J. M. and Barrett,
J. C. (2001) Diet and cancer prevention studies in
p53-deﬁcient mice. J. Nutr. 131, (Suppl), 3092S–3094S
26 Bonorden, M. J., Rogozina, O. P., Kluczny, C. M.,
Grossmann, M. E., Grambsch, P. L., Grande, J. P.,
Perkins, S., Lokshin, A. and Cleary, M. P. (2009)
Intermittent calorie restriction delays prostate tumor
detection and increases survival time in TRAMP mice.
Nutr. Cancer 61, 265–275
27 Lasko, C. M., Good, C. K., Adam, J. and Bird, R. P.
(1999) Energy restriction modulates the development of
advanced preneoplastic lesions depending on the level of
fat in the diet. Nutr. Cancer 33, 69–75
28 Lovejoy, J. C., Windhauser, M. M., Rood, J. C. and de la
Bretonne, J. A. (1998) Effect of a controlled high-fat
versus low-fat diet on insulin sensitivity and leptin levels
in African-American and Caucasian women. Metab. Clin.
Exp. 47, 1520–1524
29 Koohestani, N., Chia, M. C., Pham, N. A., Tran, T. T.,
Minkin, S., Wolever, T. M. and Bruce, W. R. (1998)
Aberrant crypt focus promotion and glucose intolerance:
correlation in the rat across diets differing in fat, n-3 fatty
acids and energy. Carcinogenesis 19, 1679–1684
30 Rao, C. V., Hirose, Y., Indranie, C. and Reddy, B. S.
(2001) Modulation of experimental colon tumorigenesis
by types and amounts of dietary fatty acids. Cancer Res.
61, 1927–1933
31 Lee, W. M., Lu, S., Medline, A. and Archer, M. C. (2001)
Susceptibility of lean and obese Zucker rats to
tumorigenesis induced by N-methyl-N-nitrosourea.
Cancer Lett. 162, 155–160
32 Koohestani, N., Tran, T. T., Lee, W., Wolever, T. M. and
Bruce, W. R. (1997) Insulin resistance and promotion of
aberrant crypt foci in the colons of rats on a high-fat diet.
Nutr. Cancer 29, 69–76
33 Tran, T. T., Gupta, N., Goh, T., Naigamwalla, D., Chia,
M. C., Koohestani, N., Mehrotra, S., McKeown-Eyssen,
G., Giacca, A. and Bruce, W. R. (2003) Direct measure of
insulin sensitivity with the hyperinsulinemic-euglycemic
clamp and surrogate measures of insulin sensitivity with
the oral glucose tolerance test: correlations with aberrant
crypt foci promotion in rats. Cancer Epidemiol.
Biomarkers Prev. 12, 47–56
34 Saydah, S. H., Platz, E. A., Rifai, N., Pollak, M. N.,
Brancati, F. L. and Helzlsouer, K. J. (2003) Association of
markers of insulin and glucose control with subsequent
colorectal cancer risk. Cancer Epidemiol. Biomarkers
Prev. 12, 412–418
35 Palmqvist, R., Stattin, P., Rinaldi, S., Biessy, C., Stenling,
R., Riboli, E., Hallmans, G. and Kaaks, R. (2003) Plasma
insulin, IGF-binding proteins-1 and -2 and risk of
colorectal cancer: a prospective study in northern Sweden.
Int. J. Cancer 107, 89–93
36 Stattin, P., Lukanova, A., Biessy, C., S¨ oderberg, S.,
Palmqvist, R., Kaaks, R., Olsson, T. and Jellum, E. (2004)
Obesity and colon cancer: does leptin provide a link? Int.
J. Cancer 109, 149–152
37 Wei, E. K., Ma, J., Pollak, M. N., Rifai, N., Fuchs, C. S.,
Hankinson, S. E. and Giovannucci, E. (2005) A
prospective study of C-peptide, insulin-like growth
factor-I, insulin-like growth factor binding protein-1, and
the risk of colorectal cancer in women. Cancer Epidemiol.
Biomarkers Prev. 14, 850–855
38 Stocks, T., Lukanova, A., Johansson, M., Rinaldi, S.,
Palmqvist, R., Hallmans, G., Kaaks, R. and P, S. (2008)
Components of the metabolic syndrome and colorectal
cancer risk; a prospective study. Int. J. Obes. 32,
304–314
39 Limburg, P. J., Stolzenberg-Solomon, R. Z., Vierkant,
R. A., Roberts, K., Sellers, T. A., Taylor, P. R., Sellers,
T. A., Taylor, P. R., Virtamo, J., Cerhan, J. R. and Albanes,
D. (2006) Insulin, glucose, insulin resistance, and incident
colorectal cancer in male smokers. Clin. Gastroenterol.
Hepatol. 4, 1514–1521
40 Kaaks, R., Toniolo, P., Akhmedkhanov, A., Lukanova, A.,
Biessy, C., Dechaud, H., Rinaldi, S., Zeleniuch-Jacquotte,
A., Shore, R. E. and Riboli, E. (2000) Serum C-peptide,
insulin-like growth factor (IGF)-I, IGF-binding proteins,
and colorectal cancer risk in women. J. Natl. Cancer Inst.
92, 1592–1600
41 Ma, J., Giovannucci, E., Pollak, M., Leavitt, A., Tao, Y.,
Gaziano, J. M. and Stampfer, M. J. (2004) A prospective
study of plasma C-peptide and colorectal cancer risk in
men. J. Natl. Cancer Inst. 96, 546–553
42 Tripkovic, I., Tripkovic, A., Strnad, M., Capkun, V. and
Zekan, L. (2007) Role of insulin-like growth factor-1 in
colon cancerogenesis: a case-control study. Arch. Med.
Res. 38, 519–525
43 Otani, T., Iwasaki, M., Sasazuki, S., Inoue, M. and
Tsugane, S. (2007) Plasma C-peptide, insulin-like growth
factor-I, insulin-like growth factor binding proteins and
risk of colorectal cancer in a nested case-control study:
the Japan public health center-based prospective study.
Int. J. Cancer 120, 2007–2012
44 Jenab, M., Riboli, E., Cleveland, R. J., Norat, T., Rinaldi,
S., Nieters, A., Biessy, C., Tjønneland, A., Olsen, A.,
Overvad, K. et al. (2007) Serum C-peptide, IGFBP-1 and
IGFBP-2 and risk of colon and rectal cancers in the
European Prospective Investigation into Cancer and
Nutrition. Int. J. Cancer 121, 368–376
45 Schoen, R. E., Weissfeld, J. L., Kuller, L. H., Thaete, F. L.,
Evans, R. W., Hayes, R. B. and Rosen, C. J. (2005)
Insulin-like growth factor-I and insulin are associated
with the presence and advancement of adenomatous
polyps. Gastroenterology 129, 464–475
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.328 I. F. Godsland
46 Keku, T. O., Lund, P. K., Galanko, J., Simmons, J. G.,
Woosley, J. T. and Sandler, R. S. (2005) Insulin resistance,
apoptosis, and colorectal adenoma risk. Cancer
Epidemiol. Biomarkers Prev. 14, 2076–2081
47 Wei, E. K., Ma, J., Pollak, M. N., Rifai, N., Fuchs, C. S.,
Hankinson, S. E. and Giovannucci, E. (2006) C-peptide,
insulin-like growth factor binding protein-1, glycosylated
hemoglobin, and the risk of distal colorectal adenoma in
women. Cancer Epidemiol. Biomarkers Prev. 15, 750–755
48 Jernstr¨ om, H. and Barrett-Connor, E. (1999) Obesity,
weight change, fasting insulin, proinsulin, C-peptide, and
insulin-like growth factor-1 levels in women with and
without breast cancer: the Rancho Bernardo Study. J.
Womens Health Gender-Based Med. 8, 1265–1272
49 Muti, P., Quattrin, T., Grant, B. J., Krogh, V., Micheli, A.,
Sch¨ unemann, H. J., Ram, M., Freudenheim, J. L., Sieri, S.,
Trevisan, M. and Berrino, F. (2002) Fasting glucose is a
risk factor for breast cancer: a prospective study. Cancer
Epidemiol. Biomarkers Prev. 11, 1361–1368
50 Mink, P. J., Shahar, E., Rosamond, W. D., Alberg, A. J.
and Folsom, A. R. (2002) Serum insulin and glucose levels
and breast cancer incidence: the Atherosclerosis Risk in
Communities Study. Am. J. Epidemiol. 156, 349–352
51 Eliassen, A. H., Tworoger, S. S., Mantzoros, C. S., Pollak,
M. N. and Hankinson, S. E. (2007) Circulating insulin and
c-peptide levels and risk of breast cancer among
predominately premenopausal women. Cancer
Epidemiol. Biomarkers Prev. 16, 161–164
52 Toniolo, P., Bruning, P. F., Akhmedkhanov, A., Bonfr` er,
J. M., Koenig, K. L., Lukanova, A., Shore, R. E. and
Zeleniuch-Jacquotte, A. (2000) Serum insulin-like growth
factor-I and breast cancer. Int. J. Cancer 88, 828–832
53 Keinan-Boker, L., Bueno De Mesquita, H. B., Kaaks, R.,
Van Gils, C. H., Van Noord, P. A., Rinaldi, S., Riboli, E.,
Seidell, J. C., Grobbee, D. E. and Peeters, P. H. (2003)
Circulating levels of insulin-like growth factor I, its
binding proteins -1,-2, -3, C-peptide and risk of
postmenopausal breast cancer. Int. J. Cancer 106, 90–95
54 Schairer, C., Hill, D., Sturgeon, S. R., Fears, T., Pollak, M.,
Mies, C., Ziegler, R. G., Hoover, R. N. and Sherman,
M. E. (2004) Serum concentrations of IGF-I, IGFBP-3
and c-peptide and risk of hyperplasia and cancer of the
breast in postmenopausal women. Int. J. Cancer 108,
773–779
55 Verheus, M., Peeters, P. H., Rinaldi, S., Dossus, L., Biessy,
C., Olsen, A., Tjønneland, A., Overvad, K., Jeppesen, M.,
Clavel-Chapelon, F. et al. (2006) Serum C-peptide levels
and breast cancer risk: results from the European
Prospective Investigation into Cancer and Nutrition
(EPIC). Int. J. Cancer 119, 659–667
56 Falk, R. T., Brinton, L. A., Madigan, M. P., Potischman,
N., Sturgeon, S. R., Malone, K. E. and Daling, J. R. (2006)
Interrelationships between serum leptin, IGF-1, IGFBP3,
C-peptide and prolactin and breast cancer risk in young
women. Breast Cancer Res. Treat. 98, 157–165
57 Del Giudice, M. E., Fantus, I. G., Ezzat, S.,
McKeown-Eyssen, G., Page, D. and Goodwin, P. J. (1998)
Insulin and related factors in premenopausal breast cancer
risk. Breast Cancer Res. Treat. 47, 111–120
58 Hirose, K., Toyama, T., Iwata, H., Takezaki, T.,
Hamajima, N. and Tajima, K. (2003) Insulin, insulin-like
growth factor-I and breast cancer risk in Japanese women.
Asian Paciﬁc J. Cancer Prev. 4, 239–246
59 Lawlor, D. A., Smith, G. D. and Ebrahim, S. (2004)
Hyperinsulinaemia and increased risk of breast cancer:
ﬁndings from the British Women’s Heart and Health
Study. Cancer Causes Control 15, 267–275
60 Gunter, M. J., Hoover, D. R., Yu, H., Wassertheil-Smoller,
S., Rohan, T. E., Manson, J. E., Li, J., Ho, G. Y., Xue, X.,
Anderson, G. L. et al. (2009) Insulin, insulin-like growth
factor-I, and risk of breast cancer in postmenopausal
women. J. Natl. Cancer Inst. 101, 48–60
61 Kabat, G. C., Kim, M., Caan, B. J., Chlebowski, R. T.,
Gunter, M. J., Ho, G. Y., Rodriguez, B. L., Shikany, J. M.,
Strickler, H. D., Vitolins, M. Z. and Rohan, T. E. (2009)
Repeated measures of serum glucose and insulin in
relation to postmenopausal breast cancer. Int. J. Cancer
125, 2704–2710
62 Bruning, P. F., Bonfr` er, J. M., van Noord, P. A., Hart,
A. A., de Jong-Bakker, M. and Nooijen, W. J. (1992)
Insulin resistance and breast-cancer risk. Int. J. Cancer 21,
511–516
63 Yang, G., Lu, G., Jin, F., Dai, Q., Best, R., Shu, X. O.,
Chen, J. R., Pan, X. Y., Shrubsole, M. and Zheng, W.
(2001) Population-based, case-control study of blood
C-peptide level and breast cancer risk. Cancer Epidemiol.
Biomarkers Prev. 10, 1207–1211
64 Malin, A., Dai, Q., Yu, H., Shu, X. O., Jin, F., Gao, Y. T.
and Zheng, W. (2004) Evaluation of the synergistic effect
of insulin resistance and insulin-like growth factors on the
risk of breast carcinoma. Cancer 100, 694–700
65 Weiderpass, E., Brismar, K., Bellocco, R., Vainio, H. and
Kaaks, R. (2003) Serum levels of insulin-like growth
factor-I, IGF-binding protein 1 and 3, and insulin and
endometrial cancer risk. Br. J. Cancer 89, 1697–1704
66 Troisi, R., Potischman, N., Hoover, R. N., Siiteri, P. and
Brinton, L. A. (1997) Insulin and endometrial cancer. Am.
J. Epidemiol 146, 476–482
67 Gunter, M. J., Hoover, D. R., Yu, H., Wassertheil-Smoller,
S., Manson, J. E., Li, J., Harris, T. G., Rohan, T. E., Xue,
X., Ho, G. Y. et al. (2008) A prospective evaluation of
insulin and insulin-like growth factor-I as risk factors for
endometrial cancer. Cancer Epidemiol. Biomarkers Prev.
17, 921–929
68 Lukanova, A., Zeleniuch-Jacquotte, A., Lundin, E.,
Micheli, A., Arslan, A. A., Rinaldi, S., Muti, P., Lenner, P.,
Koenig, K. L., Biessy, C. et al. (2004) Prediagnostic levels
of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of
endometrial cancer. Int. J. Cancer 108, 262–268
69 Cust, A. E., Allen, N. E., Rinaldi, S., Dossus, L.,
Friedenreich, C., Olsen, A., Tjønneland, A., Overvad, K.,
Clavel-Chapelon, F., Boutron-Ruault, M. C. et al. (2007)
Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and
endometrial cancer risk; results from the European
prospective investigation into cancer and nutrition. Int. J.
Cancer 120, 2656–2664
70 Stattin, P., S¨ oderberg, S., Hallmans, G., Bylund, A.,
Kaaks, R., Stenman, U. H., Bergh, A. and Olsson, T.
(2001) Leptin is associated with increased prostate cancer
risk: a nested case-referent study. J. Clin. Endocrinol.
Metab. 86, 1341–1345
71 Hubbard, J. S., Rohrmann, S., Landis, P. K., Metter, E. J.,
Muller, D. C., Andres, R., Carter, H. B. and Platz, E. A.
(2004) Association of prostate cancer risk with insulin,
glucose, and anthropometry in the Baltimore longitudinal
study of aging. Urology 63, 253–258
72 Borugian, M. J., Spinelli, J. J., Sun, Z., Kolonel, L. N.,
Oakley-Girvan, I., Pollak, M. D., Whittemore, A. S., Wu,
A. H. and Gallagher, R. P. (2007) Prediagnostic C-peptide
and risk of prostate cancer. Cancer Epidemiol.
Biomarkers Prev. 16, 2164–2165
73 Hsing, A. W., Chua, S. J., Gao, Y. T., Gentzschein, E.,
Chang, L., Deng, J. and Stanczyk, F. Z. (2001) Prostate
cancer risk and serum levels of insulin and leptin: a
population-based study. J. Natl. Cancer Inst. 93, 783–789
74 Hammarsten, J. and H¨ ogstedt, B. (2005)
Hyperinsulinaemia: a prospective risk factor for lethal
clinical prostate cancer. Eur. J. Cancer 41, 2887–2895
75 Stolzenberg-Solomon, R. Z., Graubard, B. I., Chari, S.,
Limburg, P., Taylor, P. R., Virtamo, J. and Albanes, D.
(2005) Insulin, glucose, insulin resistance, and pancreatic
cancer in male smokers. JAMA, J. Am. Med. Assoc. 294,
2872–2878
76 Michaud, D. S., Wolpin, B., Giovannucci, E., Liu, S.,
Cochrane, B., Manson, J. E., Pollak, M. N., Ma, J. and
Fuchs, C. S. (2007) Prediagnostic plasma C-peptide and
pancreatic cancer risk in men and women. Cancer
Epidemiol. Biomarkers Prev. 16, 2101–2109
77 Tande, A. J., Platz, E. A. and Folsom, A. R. (2006) The
metabolic syndrome is associated with reduced risk of
prostate cancer. Am. J. Epidemiol 164, 1094–1102
78 Stocks, T., Lukanova, A., Rinaldi, S., Biessy, C., Dossus,
L., Lindahl, B., Hallmans, G., Kaaks, R. and Stattin, P.
(2007) Insulin resistance is inversely related to prostate
cancer: a prospective study in Northern Sweden. Int. J.
Cancer 120, 2678–2686
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Insulin resistance and cancer 329
79 Moore, S. C., Leitzmann, M. F., Weinstein, S. J., Snyder,
K., Albanes, D., Virtamo, J., Graubard, B. I., Mayne, S. T.,
Yu, H., Peters, U. and MJ., G. (2007) Insulin
resistance-related gene polymorphisms and risk of
prostate cancer. Cancer Epidemiol. Biomarkers Prev. 16,
1315–1317
80 Gunter, M. J., Hayes, R. B., Chatterjee, N., Yeager, M.,
Welch, R., Schoen, R. E., Yakochi, L., Schatzkin, A. and
Peters, U. (2007) Insulin resistance-related genes and
advanced left-sided colorectal adenoma. Cancer
Epidemiol. Biomarkers Prev. 16, 703–708
81 Fall, K., Stark, J. R., Mucci, L. A., Chan, J., Stampfer,
M. J., Kurth, T., Febbo, P. G., Kantoff, P. and Ma, J. (2008)
No association between a polymorphic variant of the
IRS-1 gene and prostate cancer risk. Prostate 68,
1416–1420
82 Colangelo, L. A., Gapstur, S. M., Gann, P. H., Dyer, A. R.
and Liu, K. (2002) Colorectal cancer mortality and factors
related to the insulin resistance syndrome. Cancer
Epidemiol. Biomarkers Prev. 11, 385–391
83 Ahmed, R. L., Schmitz, K. H., Anderson, K. E.,
Rosamond, W. D. and Folsom, A. R. (2006) The
metabolic syndrome and risk of incident colorectal
cancer. Cancer 107, 28–36
84 Bowers, K., Albanes, D., Limburg, P., Pietinen, P., Taylor,
P. R., Virtamo, J. and Stolzenberg-Solomon, R. Z. (2006)
A prospective study of anthropometric and clinical
measurements associated with insulin resistance
syndrome and colorectal cancer in male smokers. Am. J.
Epidemiol. 164, 652–664
85 St¨ urmer, T., Buring, J. E., Lee, I. M., Gaziano, J. M. and
Glynn, R. J. (2006) Metabolic abnormalities and risk for
colorectal cancer in the Physicians’ Health Study. Cancer
Epidemiol. Biomarkers Prev. 15, 2391–2397
86 Pasanisi, P., Berrino, F., De Petris, M., Venturelli, E.,
Mastroianni, A. and Panico, S. (2006) Metabolic
syndrome as a prognostic factor for breast cancer
recurrences. Int. J. Cancer 119, 236–238
87 Lund H˚ aheim, L., Wisløff, T. F., Holme, I. and Nafstad, P.
(2006) Metabolic syndrome predicts prostate cancer in a
cohort of middle-aged Norwegian men followed for 27
years. Am. J. Epidemiol. 164, 769–774
88 Yancik, R., Wesley, M. N., Ries, L. A., Havlik, R. J.,
Edwards, B. K. and Yates, J. W. (2001) Effect of age and
comorbidity in postmenopausal breast cancer patients
aged 55 years and older. JAMA, J. Am. Med. Assoc. 285,
885–892
89 Calle, E. E., Rodriguez, C., Walker-Thurmond, K. and
Thun, M. J. (2003) Overweight, obesity, and mortality
from cancer in a prospectively studied cohort of U.S.
adults. N. Engl. J. Med. 348, 1625–1638
90 Hammarsten, J. and H¨ ogstedt, B. (2004) Clinical,
haemodynamic, anthropometric, metabolic and insulin
proﬁle of men with high-stage and high-grade clinical
prostate cancer. Blood Press. 13, 47–55
91 Wright, M. E., Chang, S. C., Schatzkin, A., Albanes, D.,
Kipnis, V., Mouw, T., Hurwitz, P., Hollenbeck, A. and
Leitzmann, M. F. (2007) Prospective study of adiposity
and weight change in relation to prostate cancer incidence
and mortality. Cancer 109, 675–684
92 Ma, J., Li, H., Giovannucci, E., Mucci, L., Qiu, W.,
Nguyen, P. L., Gaziano, J. M., Pollak, M. and Stampfer,
M. J. (2008) Prediagnostic body-mass index, plasma
C-peptide concentration, and prostate cancer-speciﬁc
mortality in men with prostate cancer: a long-term
survival analysis. Lancet Oncol. 9, 1039–1047
93 Vigneri, P., Frasca, F., Sciacca, L., Pandini, G. and Vigneri,
R. (2009) Diabetes and cancer, Endocr. Relat. Cancer, doi:
10.1677/ERC-09-0087
94 Schimmack, G., Defronzo, R. A. and Musi, N. (2006)
AMP-activated protein kinase: Role in metabolism and
therapeutic implications. Diabetes Obes. Metab. 8,
591–602
95 Xiang, X., Saha, A. K., Wen, R., Ruderman, N. B. and
Luo, Z. (2004) AMP-activated protein kinase activators
can inhibit the growth of prostate cancer cells by multiple
mechanisms. Biochem. Biophys. Res. Commun. 321,
161–167
96 Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M.,
Alessi, D. R. and Morris, A. D. (2005) Metformin and
reduced risk of cancer in diabetic patients. Br. Med. J. 330,
1304–1305
97 Bowker, S. L., Majumdar, S. R., Veugelers, P. and Johnson,
J. A. (2006) Increased cancer-related mortality for patients
with type 2 diabetes who use sulfonylureas or insulin.
Diabetes Care 29, 254–258
98 Currie, C. J., Poole, C. D. and Gale, E. A. (2009) The
inﬂuence of glucose-lowering therapies on cancer risk in
type 2 diabetes. Diabetologia 52, 1766–1777
99 Donadon, V., Balbi, M., Ghersetti, M., Grazioli, S.,
Perciaccante, A., Della Valentina, G., Gardenal, R., Dal
Mas, M., Casarin, P., Zanette, G. and Miranda, C. (2009)
Antidiabetic therapy and increased risk of hepatocellular
carcinoma in chronic liver disease. World J.
Gastroenterol. 15, 2506–2511
100 Ben Sahra, I., Laurent, K., Loubat, A., Giorgetti-Peraldi,
S., Colosetti, P., Auberger, P., Tanti, J. F., Le Marchand-
Brustel, Y. and Bost, F. (2008) The antidiabetic drug
metformin exerts an antitumoral effect in vitro and in
vivo through a decrease of cyclin D1 level. Oncogene 27,
3576–3586
101 Vazquez-Martin, A., Oliveras-Ferraros, C. and
Menendez, J. A. (2009) The antidiabetic drug metformin
suppresses HER2 (erbB-2) oncoprotein overexpression
via inhibition of the mTOR effector p70S6K1 in human
breast carcinoma cells. Cell Cycle 8, 88–96
102 Yang, Y. X., Hennessy, S. and Lewis, J. D. (2004) Insulin
therapy and colorectal cancer risk among type 2 diabetes
mellitus patients. Gastroenterology 127, 1044–1050
103 Chung, Y. W., Han, D. S., Park, K. H., Eun, C. S., Yoo,
K. S. and Park, C. K. (2008) Insulin therapy and colorectal
adenoma risk among patients with Type 2 diabetes
mellitus: a case-control study in Korea. Dis. Colon
Rectum 51, 593–597
104 Hemkens, L. G., Grouven, U., Bender, R., G¨ unster, C.,
Gutschmidt, S., Selke, G. W. and Sawicki, P. T. (2009) Risk
of malignancies in patients with diabetes treated with
human insulin or insulin analogues: a cohort study.
Diabetologia 52, 1732–1744
105 Jørgensen, L. N., Dideriksen, L. H. and Drejer, K. (1992)
Carcinogenic effect of the human insulin analogue B10
Asp in female rats. Diabetologia 35, (Suppl 1),
A3
106 Milazzo, G., Sciacca, L., Papa, V., Goldﬁne, I. D. and
Vigneri, R. (1997) ASPB10 insulin induction of increased
mitogenic responses and phenotypic changes in human
breast epithelial cells: evidence for enhanced interactions
with the insulin-like growth factor-I receptor. Mol.
Carcinog. 18, 19–25
107 Weinstein, D., Simon, M., Yehezkel, E., Laron, Z. and
Werner, H. (2009) Insulin analogues display IGF-I-like
mitogenic and anti-apoptotic activities in cultured cancer
cells. Diabetes Metab. Res. Rev. 25, 41–49
108 Jonasson, J. M., Ljung, R., Talb¨ ack, M., Haglund, B.,
Gudbj¨ ornsd` ottir, S. and Steineck, G. (2009) Insulin
glargine use and short-term incidence of malignancies-a
population-based follow-up study in Sweden.
Diabetologia 52, 1745–1754
109 Colhoun, H. M. SDRN, Epidemiology and Group (2009)
Use of insulin glargine and cancer incidence in
Scotland: a study from the Scottish Diabetes Research
Network Epidemiology Group. Diabetologia 52,
1755–1765
110 Hansen, B. F. (2008) Insulin analogues with increased
mitogenic potency–are they safe? Horm. Metab. Res. 40,
431–433
111 Sandow, J. (2009) Growth effects of insulin and insulin
analogues. Arch. Physiol. Biochem. 115, 72–85
112 Monami, M., Lamanna, C., Pala, L., Bardini, G., Cresci,
B., Francesconi, P., Balzi, D., Marchionni, N., Rotella,
C. M. and Mannucci, E. (2008) Treatment with insulin
secretagogues and cancer-related mortality in type 2
diabetic patients a retrospective cohort study. Exp. Clin.
Endocrinol. Diabetes 116, 184–189
113 Stout, R. W. and Vallence-Owen, J. (1969) Insulin and
atheroma. Lancet i, 1078–1080
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.330 I. F. Godsland
114 Heuson, J. C., Coune, A. and Heimann, R. (1967) Cell
proliferation induced by insulin in organ culture of rat
mammary carcinoma. Exp. Cell Res. 45, 351–360
115 Heuson, J. C. and Legros, N. (1970) Effect of insulin and
of alloxan diabetes on growth of the rat mammary
carcinoma in vivo. Eur. J. Cancer 6, 349–351
116 Lawlor, M. A. and Alessi, D. R. (2001) PKB/Akt: a key
mediator of cell proliferation, survival and insulin
responses? J. Cell Sci. 114, 2903–2910
117 Weijzen, S., Velders, M. P. and Kast, W. M. (1999)
Modulation of the immune response and tumor growth
by activated Ras. Leukemia 13, 502–513
118 Belﬁore, A., Frittitta, L., Costantino, A., Frasca, F.,
Pandini, G., Sciacca, L., Goldﬁne, I. D. and Vigneri, R.
(1996) Insulin receptors in breast cancer. Ann. N.Y. Acad.
Sci. 784, 173–188
119 King, G. L., Kahn, C. R., Rechler, M. M. and Nissley, S. P.
(1980) Direct demonstration of separate receptors for
growth and metabolic activities of insulin and
multiplication-stimulating activity (an insulinlike growth
factor) using antibodies to the insulin receptor. J. Clin.
Invest. 66, 130–140
120 Gliozzo, B., Sung, C. K., Scalia, P., Papa, V., Frasca, F.,
Sciacca, L., Giorgino, F., Milazzo, G., Goldﬁne, I. D.,
Vigneri, R. and Pezzino, V. (1998) Insulin-stimulated cell
growth in insulin receptor substrate-1-deﬁcient ZR-75–71
cells is mediated by a phosphatidylinositol-3-kinase-
independent pathway. J. Cell. Biochem. 70, 268–280
121 Goalstone, M. L. and Draznin, B. (1996) Effect of insulin
on farnesyltransferase activity in 3T3-L1 adipocytes.
J. Biol. Chem. 271, 27585–27589
122 Goalstone, M., Leitner, J. W. and Draznin, B. (1997) GTP
loading of farnesylated p21Ras by insulin at the plasma
membrane. Biochem. Biophys. Res. Commun. 239,
42–45
123 Goalstone, M. L., Leitner, J. W., Berhanu, P., Sharma,
P. M., Olefsky, J. M. and Draznin, B. (2001) Insulin
signals to prenyltransferases via the Shc branch of
intracellular signaling. J. Biol. Chem. 276,
12805–12812
124 Kao, A. W., Waters, S. B., Okada, S. and Pessin, J. E.
(1997) Insulin stimulates the phosphorylation of the 66-
and 52-kilodalton Shc isoforms by distinct pathways.
Endocrinology 138, 2474–2480
125 Migliaccio, E., Mele, S., Salcini, A. E., Pelicci, G., Lai,
K. M., Superti-Furga, G., Pawson, T., Di Fiore, P. P.,
Lanfrancone, L. and Pelicci, P. G. (1997) Opposite effects
of the p52shc/p46shc and p66shc splicing isoforms on the
EGF receptor-MAP kinase-fos signalling pathway.
EMBO J. 16, 706–716
126 Goalstone, M. L., Leitner, J. W., Wall, K., Dolgonos, L.,
Rother, K. I., Accili, D. and Draznin, B. (1998) Effect of
insulin on farnesyltransferase. Speciﬁcity of insulin action
and potentiation of nuclear effects of insulin-like growth
factor-1, epidermal growth factor, and platelet-derived
growth factor. J. Biol. Chem. 273, 23892–23896
127 Leitner, J. W., Kline, T., Carel, K., Goalstone, M. and
Draznin, B. (1997) Hyperinsulinemia potentiates
activation of p21Ras by growth factors. Endocrinology
138, 2211–2214
128 Goalstone, M. L., Wall, K., Leitner, J. W., Kurowski, T.,
Ruderman, N., Pan, S. J., Ivy, J. L., Moller, D. E. and
Draznin, B. (1999) Increased amounts of farnesylated
p21Ras in tissues of hyperinsulinaemic animals.
Diabetologia 42, 310–316
129 Goalstone, M. L. and Draznin, B. (1998) What does
insulin do to Ras? Cell. Signalling 10, 297–301
130 Goalstone, M. L., Natarajan, R., Standley, P. R., Walsh,
M. F., Leitner, J. W., Carel, K., Scott, S., Nadler, J.,
Sowers, J. R. and Draznin, B. (1998) Insulin potentiates
platelet-derived growth factor action in vascular smooth
muscle cells. Endocrinology 139, 4067–4067
131 Giorgino, F., Belﬁore, A., Milazzo, G., Costantino, A.,
Maddux, B., Whittaker, J., Goldﬁne, I. D. and Vigneri, R.
(1991) Overexpression of insulin receptors in ﬁbroblast
and ovary cells induces a ligand-mediated transformed
phenotype. Mol. Endocrinol. 5, 452–459
132 Frittitta, L., Vigneri, R., Stampfer, M. R. and Goldﬁne,
I. D. (1995) Insulin receptor overexpression in 184B5
human mammary epithelial cells induces a
ligand-dependent transformed phenotype. J. Cell.
Biochem. 57, 666–669
133 Papa, V., Pezzino, V., Costantino, A., Belﬁore, A.,
Giuffrida, D., Frittitta, L., Vannelli, G. B., Brand, R.,
Goldﬁne, I. D. and Vigneri, R. (1990) Elevated insulin
receptor content in human breast cancer. J. Clin. Invest.
86, 1503–1510
134 Milazzo, G., Giorgino, F., Damante, G., Sung, C.,
Stampfer, M. R., Vigneri, R., Goldﬁne, I. D. and Belﬁore,
A. (1992) Insulin receptor expression and function in
human breast cancer cell lines. Cancer Res. 52,
3924–3930
135 Finlayson, C. A., Chappell, J., Leitner, J. W., Goalstone,
M. L., Garrity, M., Nawaz, S., Ciaraldi, T. P. and Draznin,
B. (2003) Enhanced insulin signaling via Shc in human
breast cancer. Metab. Clin. Exp. 52, 1606–1611
136 Frittitta, L., Vigneri, R., Papa, V., Goldﬁne, I. D., Grasso,
G. and Trischitta, V. (1993) Structural and functional
studies of insulin receptors in human breast cancer. Breast
Cancer Res. Treat. 25, 73–82
137 Frasca, F., Pandini, G., Scalia, P., Sciacca, L., Mineo, R.,
Costantino, A., Goldﬁne, I. D., Belﬁore, A. and Vigneri,
R. (1999) Insulin receptor isoform A, a newly recognized,
high-afﬁnity insulin-like growth factor II receptor in fetal
and cancer cells. Mol. Cell. Biol. 19, 3278–3288
138 Mountjoy, K. G., Finlay, G. J. and Holdaway, I. M. (1987)
Abnormal insulin-receptor down regulation and
dissociation of down regulation from insulin biological
action in cultured human tumor cells. Cancer Res. 47,
6500–6504
139 Jhun, B. H., Meinkoth, J. L., Leitner, J. W., Draznin, B.
and Olefsky, J. M. (1994) Insulin and insulin-like growth
factor-I signal transduction requires p21ras. J. Biol.
Chem. 269, 5699–5704
140 Draznin, B., Chang, L., Leitner, J. W., Takata, Y. and
Olefsky, J. M. (1993) Insulin activates p21Ras and guanine
nucleotide releasing factor in cells expressing wild
type and mutant insulin receptors. J. Biol. Chem. 25,
19998–20001
141 Burgering, B. M., Snijders, A. J., Maassen, J. A., van der
Eb, A. J. and Bos, J. L. (1989) Possible involvement of
normal p21 H-ras in the insulin/insulinlike growth factor
1 signal transduction pathway. Mol. Cell. Biol. 9,
4312–4322
142 Yu, H. and Rohan, T. (2000) Role of the insulin-like
growth factor family in cancer development and
progression. J. Natl. Cancer Inst. 92, 1472–1489
143 Wu, Y., Yakar, S., Zhao, L., Hennighausen, L. and
LeRoith, D. (2002) Circulating insulin-like growth
factor-I levels regulate colon cancer growth and
metastasis. Cancer Res. 62, 1030–1035
144 Bhalla, V., Joshi, K., Vohra, H., Singh, G. and Ganguly,
N. K. (2000) Effect of growth factors on proliferation of
normal, borderline, and malignant breast epithelial cells.
Exp. Mol. Pathol. 68, 124–132
145 Hadsell, D. L., Murphy, K. L., Bonnette, S. G., Reece, N.,
Laucirica, R. and Rosen, J. M. (2000) Cooperative
interaction between mutant p53 and des(1–3)IGF-I
accelerates mammary tumorigenesis. Oncogene 19,
889–898
146 Wu, Y., Cui, K., Miyoshi, K., Hennighausen, L., Green,
J. E., Setser, J., LeRoith, D. and Yakar, S. (2003) Reduced
circulating insulin-like growth factor I levels delay the
onset of chemically and genetically induced mammary
tumors. Cancer Res. 63, 4384–4388
147 Kari, F. W., Dunn, S. E., French, J. E. and Barrett, J. C.
(1999) Roles for insulin-like growth factor-1 in mediating
the anti-carcinogenic effects of caloric restriction. J. Nutr.
Health Aging 3, 92–101
148 Oh, J. S., Kucab, J. E., Bushel, P. R., Martin, K., Bennett,
L., Collins, J., DiAugustine, R. P., Barrett, J. C., Afshari,
C. A. and Dunn, S. E. (2002) Insulin-like growth factor-1
inscribes a gene expression proﬁle for angiogenic factors
and cancer progression in breast epithelial cells. Neoplasia
4, 204–217
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.Insulin resistance and cancer 331
149 Ibrahim, Y. H. and Yee, D. (2004) Insulin-like growth
factor-I and cancer risk. Growth Horm. IGF Res. 14,
261–269
150 Kato, S., Masuhiro, Y., Watanabe, M., Kobayashi, Y.,
Takeyama, K. I., Endoh, H. and Yanagisawa, J. (2000)
Molecular mechanism of a cross-talk between oestrogen
and growth factor signalling pathways. Genes Cells 5,
593–601
151 Bailyes, E. M., Nav´ e, B. T., Soos, M. A., Orr, S. R.,
Hayward, A. C. and Siddle, K. (1997) Insulin
receptor/IGF-I receptor hybrids are widely distributed in
mammalian tissues: quantiﬁcation of individual receptor
species by selective immunoprecipitation and
immunoblotting. Biochem. J. 327, 209–215
152 Flier, J. S., Usher, P. and Moses, A. C. (1986) Monoclonal
antibody to the type I insulin-like growth factor (IGF-I)
receptor blocks IGF-I receptor-mediated DNA synthesis:
clariﬁcation of the mitogenic mechanisms of IGF-I and
insulin in human skin ﬁbroblasts. Proc. Natl. Acad. Sci.
U.S.A. 83, 664–668
153 Wolk, A., Mantzoros, C. S., Andersson, S. O., Bergstrom,
R., Signorello, L. B., Lagiou, P., Adami, H. O. and
Trichopoulos, D. (1998) Insulin-like growth factor 1 and
prostate cancer risk: a population- based, case-control
study. J. Natl. Cancer Inst. 90, 911–915
154 Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann,
P. H., Ma, J., Wilkinson, P., Hennekens, C. H. and Pollak,
M. (1998) Plasma insulin-like growth factor-I and
prostate cancer risk: a prospective study. Science 279,
563–566
155 Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter,
D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E.
and Pollak, M. (1998) Circulating concentrations of
insulin-like growth factor-I and risk of breast cancer.
Lancet 351, 1393–1396
156 Ma, J., Pollak, M. N., Giovannucci, E., Chan, J. M., Tao,
Y., Hennekens, C. H. and Stampfer, M. J. (1999)
Prospective study of colorectal cancer risk in men and
plasma levels of insulin-like growth factor (IGF)-I and
IGF-binding protein-3. J. Natl. Cancer Inst. 91,
620–625
157 Yu, H., Spitz, M. R., Mistry, J., Gu, J., Hong, W. K. and
Wu, X. (1999) Plasma levels of insulin-like growth
factor-I and lung cancer risk: a case-control analysis.
J. Natl. Cancer Inst. 91, 151–156
158 Leung, K. C., Doyle, N., Ballesteros, M., Waters, M. J.
and Ho, K. K. (2000) Insulin regulation of human hepatic
growth hormone receptors: divergent effects on
biosynthesis and surface translocation. J. Clin.
Endocrinol. Metab. 85, 4712–4720
159 Roberts, C. T. J., Brown, A. L., Graham, D. E., Seelig, S.,
Berry, S., Gabbay, K. H. and Rechler, M. M. (1986)
Growth hormone regulates the abundance of insulin-like
growth factor I RNA in adult rat liver. J. Biol. Chem. 261,
10025–10028
160 Zapf, J., Walter, H. and Froesch, E. R. (1981)
Radioimmunological determination of insulinlike growth
factors I and II in normal subjects and in patients with
growth disorders and extrapancreatic tumor
hypoglycemia. J. Clin. Invest. 68, 1321–1330
161 Pandini, G., Vigneri, R., Costantino, A., Frasca, F.,
Ippolito, A., Fujita-Yamaguchi, Y., Siddle, K., Goldﬁne,
I. D. and Belﬁore, A. (1999) Insulin and insulin-like
growth factor-I (IGF-I) receptor overexpression
in breast cancers leads to insulin/IGF-I hybrid
receptor overexpression: evidence for a second
mechanism of IGF-I signaling. Clin. Cancer Res. 5,
1935–1944
162 Freier, S., Weiss, O., Eran, M., Flyvbjerg, A., Dahan, R.,
Nephesh, I., Safra, T., Shiloni, E. and Raz, I. (1999)
Expression of the insulin-like growth factors and their
receptors in adenocarcinoma of the colon. Gut 44,
704–708
163 Frasca, F., Pandini, G., Sciacca, L., Pezzino, V., Squatrito,
S., Belﬁore, A. and Vigneri, R. (2008) The role of insulin
receptors and IGF-I receptors in cancer and other
diseases. Arch. Physiol. Biochem. 114, 23–37
164 Pandini, G., Frasca, F., Mineo, R., Sciacca, L., Vigneri, R.
and Belﬁore, A. (2002) Insulin/insulin-like growth factor
I hybrid receptors have different biological characteristics
depending on the insulin receptor isoform involved.
J. Biol. Chem. 277, 39684–39695
165 Oh, Y., M¨ uller, H. L., Lamson, G. and Rosenfeld, R. G.
(1993) Insulin-like growth factor (IGF)-independent
action of IGF-binding protein-3 in Hs578T human breast
cancer cells. Cell surface binding and growth inhibition.
J. Biol. Chem. 268, 14964–14971
166 Oh, S. H., Kim, W. Y., Kim, J. H., Younes, M. N.,
El-Naggar, A. K., Myers, J. N., Kies, M., Cohen, P., Khuri,
F., Hong, W. K. and Lee, H. Y. (2006) Identiﬁcation of
insulin-like growth factor binding protein-3 as a farnesyl
transferase inhibitor SCH66336-induced negative
regulator of angiogenesis in head and neck squamous cell
carcinoma. Clin. Cancer Res. 15, 653–661
167 Rajah, R., Valentinis, B. and Cohen, P. (1997) Insulin-like
growth factor (IGF)-binding protein-3 induces apoptosis
and mediates the effects of transforming growth factor-1
on programmed cell death through a p53- and IGF-
independent mechanism. J. Biol. Chem. 272,
12181–12188
168 Williams, A. C., Collard, T. J., Perks, C. M., Newcomb,
P., Moorghen, M., Holly, J. M. and Paraskeva, C. (2000)
Increased p53-dependent apoptosis by the insulin-like
growth factor binding protein IGFBP-3 in human colonic
adenoma-derived cells. Cancer Res. 60, 22–27
169 Villafuerte, B. C., Zhang, W. N. and Phillips, L. S. (1996)
Insulin and insulin-like growth factor-I regulate hepatic
insulin-like growth factor binding protein-3 by different
mechanisms. Mol. Endocrinol. 10, 622–630
170 Snyder, D. K. and Clemmons, D. R. (1990)
Insulin-dependent regulation of insulin-like growth
factor-binding protein-1. J. Clin. Endocrinol. Metab. 71,
1632–1636
171 Powell, D. R., Suwanichkul, A., Cubbage, M. L.,
DePaolis, L. A., Snuggs, M. B. and Lee, P. D. (1991)
Insulin inhibits transcription of the human gene for
insulin-like growth factor-binding protein-1. J. Biol.
Chem. 266, 18868–18876
172 Clemmons, D. R., Snyder, D. K. and Busby, W. H. J.
(1991) Variables controlling the secretion of insulin-like
growth factor binding protein-2 in normal human
subjects. J. Clin. Endocrinol. Metab. 73, 727–733
173 Rajaram, S., Baylink, D. J. and Mohan, S. (1997)
Insulin-like growth factor-binding proteins in serum and
other biological ﬂuids: regulation and functions. Endocr.
Rev. 18, 801–831
174 Baxter, R. C. (1994) Insulin-like growth factor binding
proteins in the human circulation: a review. Horm. Res.
42, 140–144
175 Hussain, S. P. and Harris, C. C. (2007) Inﬂammation and
cancer: an ancient link with novel potentials. Int. J.
Cancer 121, 2373–2380
176 Federico, A., Morgillo, F., Tuccillo, C., Ciardiello, F. and
Loguercio, C. (2007) Chronic inﬂammation and oxidative
stress in human carcinogenesis. Int. J. Cancer 121,
2381–2386
177 Mantovani, A., Allavena, P., Seca, A. and Balkwill, F.
(2008) Cancer-related inﬂamation. Nature 454, 436–444
178 Nishikawa, T. and Araki, E. (2007) Impact of
mitochondrial ROS production in the pathogenesis of
diabetes mellitus and its complications. Antioxid. Redox
Signaling 9, 343–353
179 Martien, S. and Abbadie, C. (2007) Acquisition of
oxidative DNA damage during senescence: the ﬁrst step
toward carcinogenesis? Ann. N.Y. Acad. Sci. 1119,
51–63
180 King, G. L. and Loeken, M. R. (2004)
Hyperglycemia-induced oxidative stress in diabetic
complications. Histochem. Cell. Biol. 122, 333–338
181 Nakamura, S., Takamura, T., Matsuzawa-Nagata, N.,
Takayama, H., Misu, H., Noda, H., Nabemoto, S., Kurita,
S., Ota, T., Ando, H. et al. (2009) Palmitate induces
insulin resistance in H4IIEC3 hepatocytes through
reactive oxygen species produced by mitochondria.
J. Biol. Chem. 284, 14809–14818
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.332 I. F. Godsland
182 Shoelson, S. E., Lee, J. and Goldﬁne, A. B. (2006)
Inﬂammation and insulin resistance. J. Clin. Invest. 116,
1793–1801
183 Yuan, M., Konstantopoulos, N., Lee, J., Hansen, L., Li,
Z. W., Karin, M. and Shoelson, S. E. (2001) Reversal of
obesity- and diet-induced insulin resistance with
salicylates or targeted disruption of Ikkβ. Science 293,
1673–1677
184 Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J.,
Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens,
F., Senn, H. J. and M, T. (2009) Aspirin and non-steroidal
anti-inﬂammatory drugs for cancer prevention: an
international consensus statement. Lancet Oncol. 10,
501–507
185 Tegeder, I., Pfeilschifter, J. and Geisslinger, G. (2001)
Cyclooxygenase-independent actions of cyclooxygenase
inhibitors. FASEB J. 15, 2057–2072
186 Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. and
Glass, C. K. (1998) The peroxisome proliferator-activated
receptor-γ is a negative regulator of macrophage
activation. Nature 391, 79–82
187 Kitamura, S., Miyazaki, Y., Shinomura, Y., Kondo, S.,
Kanayama, S. and Matsuzawa, Y. (1999) Peroxisome
proliferator-activated receptor γ induces growth arrest
and differentiation markers of human colon cancer cells.
Jpn J. Cancer Res. 90, 75–80
188 Housa, D., Housov´ a, J., Vernerov´ a, Z. and Haluz´ ık, M.
(2006) Adipocytokines and cancer. Physiol. Res. 55,
233–244
189 Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L.
and Spiegelman, B. M. (1995) Increased adipose tissue
expression of tumour necrosis factor-α in human obesity
and insulin resistance. J. Clin. Invest. 95, 2409–2415
190 Xu, W. H., Matthews, C. E., Xiang, Y. B., Zheng, W.,
Ruan, Z. X., Cheng, J. R., Gao, Y. T. and Shu, X. O.
(2005) Effect of adiposity and fat distribution on
endometrial cancer risk in Shanghai women. Am. J.
Epidemiol. 161, 939–947
191 Folsom, A. R., Kaye, S. A., Prineas, R. J., Potter, J. D.,
Gapstur, S. M. and Wallace, R. B. (1990) Increased
incidence of carcinoma of the breast associated with
abdominal adiposity in postmenopausal women. Am. J.
Epidemiol. 131, 794–803
192 Kaaks, R., Van Noord, P. A., Den Tonkelaar, I., Peeters,
P. H., Riboli, E. and Grobbee, D. E. (1998) Breast-cancer
incidence in relation to height, weight and body-fat
distribution in the Dutch “DOM” cohort. Int. J. Cancer
76, 647–651
193 Huang, Z., Willett, W. C., Colditz, G. A., Hunter, D. J.,
Manson, J. E., Rosner, B., Speizer, F. E. and SE, H. (1999)
Waist circumference, waist:hip ratio, and risk of breast
cancer in the Nurses’ Health Study. Am. J. Epidemiol 150,
1316–1324
194 Leyva, F., Godsland, I. F., Ghatei, M., Proudler, A. J.,
Aldis, S., Walton, C., Bloom, S. and Stevenson, J. C.
(1998) Hyperleptinaemia as a component of a metabolic
syndrome of cardiovascular risk. Arterioscler. Thromb.
Vasc. Biol. 18, 928–933
195 S´ ainz, N., Rodr´ ıguez, A., Catal´ an, V., Becerril, S.,
Ram´ ırez, B., G´ omez-Ambrosi, J. and Fr¨ uhbeck, G. (2009)
Leptin administration favors muscle mass accretion by
decreasing FoxO3a and increasing PGC-1α in ob/ob
mice. PLoS One 4, e6808
196 Ray, A., Nkhata, K. J. and Cleary, M. P. (2007) Effects of
leptin on human breast cancer cell lines in relationship to
estrogen receptor and HER2 status. Int. J. Oncol. 30,
1499–1509
197 Somasundar, P., McFadden, D. W., Hileman, S. M. and
Vona-Davis, L. (2004) Leptin is a growth factor in cancer.
J. Surg. Res. 116, 337–349
198 Magofﬁn, D. A., Weitsman, S. R., Aagarwal, S. K. and
Jakimiuk, A. J. (1999) Leptin regulation of aromatase
activity in adipose stromal cells from regularly cycling
women. Ginekol. Pol. 70, 1–7
199 Kadowaki, T., Yamauchi, T., Kubota, N., Hara, K., Ueki,
K. and Tobe, K. (2006) Adiponectin and adiponectin
receptors in insulin resistance, diabetes, and the metabolic
syndrome. J. Clin. Invest. 116, 1784–1792
200 Sugiyama, M., Takahashi, H., Hosono, K., Endo, H.,
Kato, S., Yoneda, K., Nozaki, Y., Fujita, K., Yoneda, M.,
Wada, K. et al. (2009) Adiponectin inhibits colorectal
cancer cell growth through the AMPK/mTOR pathway.
Int. J. Oncol. 34, 339–344
201 Ouchi, N., Kihara, S., Arita, Y., Okamoto, Y., Maeda, K.,
Kuriyama, H., Hotta, K., Nishida, M., Takahashi, M.,
Muraguchi, M. et al. (2000) Adiponectin, an
adipocyte-derived plasma protein, inhibits endothelial
NF-κB signaling through a cAMP-dependent pathway.
Circulation 102, 1296–1301
202 Key, T. J., Appleby, P. N., Reeves, G. K., Roddam, A.,
Dorgan, J. F., Longcope, C., Stanczyk, F. Z., Stephenson,
H. E. J., Falk, R. T., Miller, R. et al. (2003) Body mass
index, serum sex hormones, and breast cancer risk in
postmenopausal women. J. Natl. Cancer Inst. 95,
1218–1226
203 Plymate, S. R., Matej, L. A., Jones, R. E. and Friedl, K. E.
(1988) Inhibition of sex hormone-binding globulin
production in the human hepatoma (Hep G2) cell line by
insulin and prolactin. J. Clin. Endocrinol. Metab. 67,
460–464
204 Pugeat, M., Crave, J. C., Elmidani, M., Nicolas, M. H.,
Garoscio-Cholet, M., Lejeune, H., D´ echaud, H. and
Tourniaire, J. (1991) Pathophysiology of sex hormone
binding globulin (SHBG): relation to insulin. J. Steroid
Biochem. Mol. Biol. 40, 841–849
205 Reed, M. J. and Purohit, A. (1997) Breast cancer and the
role of cytokines in regulating estrogen synthesis: an
emerging hypothesis. Endocr. Rev. 18, 701–715
206 Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand,
S. L., Tatar, M. and Sinclair, D. (2004) Sirtuin activators
mimic caloric restriction and delay ageing in metazoans.
Nature 430, 686–689
207 Brooks, C. and Gu, W. (2009) How does SIRT1 affect
metabolism, senescence and cancer? Nat. Rev. Cancer 9,
123–128
208 Liang, F., Kume, S. and Koya, D. (2009) SIRT1 and
insulin resistance. Nat. Rev. Endocrinol 5, 367–373
209 Luo, J., Nikolaev, A. Y., Imai, S., Chen, D., Su, F., Shiloh,
A., Guarente, L. and Gu, W. (2001) Negative control of
p53 by Sir2α promotes cell survival under stress. Cell 107,
137–148
210 Nemoto, S., Fergusson, M. M. and Finkel, T. (2004)
Nutrient availability regulates SIRT1 through a
forkhead-dependent pathway. Science 306, 2105–2108
211 Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F.,
Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky,
R., Cohen, H. Y. et al. (2004) Stress-dependent regulation
of FOXO transcription factors by the SIRT1 deacetylase.
Science 26, 2011–2015
212 Firestein, R., Blander, G., Michan, S., Oberdoerffer, P.,
Ogino, S., Campbell, J., Bhimavarapu, A., Luikenhuis, S.,
de Cabo, R., Fuchs, C. et al. (2008) The SIRT1 deacetylase
suppresses intestinal tumorigenesis and colon cancer
growth. PLoS One 3, e2020
Received 27 July 2009/14 September 2009; accepted 21 September 2009
Published on the Internet 23 November 2009, doi:10.1042/CS20090399
C   The Authors Journal compilation C   2010 Biochemical Society
© 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.